Insulin/IGF/relaxin family polypeptides and DNAS thereof
View Patent ↗The present invention relates to (1) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:7 (A chain), (2) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:8 (B chain), (3) a polypeptide wherein the A and B chains are bonded to each other via disulfide bonds (2 chains) or its salt, (4) DNAs encoding the same, etc. These polypeptides and DNAs encoding the same can be used for the diagnosis, treatment, prevention, etc. for diseases, including abnormalities (e.g., diabetes mellitus, etc.) in metabolic regulation (sugar metabolism, lipid metabolism, etc.) of energy sources such as carbohydrates.
1. An isolated polypeptide having the amino acid sequence represented by SEQ ID NO:7, its amide or ester, or a salt thereof or the amino acid sequence represented by SEQ ID NO:8, its amide or ester, or a salt thereof.
2. An isolated polypeptide or its amide or ester, or a salt thereof according to claim 1 which contains a first amino acid segment comprising the amino acid sequence represented by SEQ ID NO:7, and a second amino acid segment comprising the amino acid sequence represented by SEQ ID NO:8.
3. An isolated polypeptide or its amide or ester, or a salt thereof, of claim 2 , wherein the first amino acid segment and die second amino acid segment are bonded together through disulfide bonds.
4. An isolated polypeptide or its amide or ester, or a salt thereof, according to claim 1 , comprising the amino acid sequence represented by SEQ ID NO:3.
5. A method of screening a compound that promotes or inhibits the activity of a polypeptide or its amide or ester, or a salt thereof, according to claim 1 which comprises comparing
(i) the binding when a polypeptide of claim 1 is brought into contact with tissues, cells or membrane fractions thereof, to:
(ii) the binding when a polypeptide of claim 1 is brought into contact with tissues, cells or membrane fractions thereof, in the presence of a test compound, and
(iii) determining if the binding of said isolated polypeptide to the said tissues, cells or membrane fractions is increased or inhibited by the test compound.
6. A kit for screening a compound or its salt that promotes or inhibits the activity of a polypeptide or its amide or ester, or a salt thereof according to claim 1 , comprising a polypeptide or its amide or ester, or a salt thereof, according to claim 1 .
7. A pharmaceutical composition comprising a polypeptide, its amide or ester, or a salt thereof, according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
8. A method for making a pharmaceutical for preventing or treating abnormality of metabolic regulation inhibition of growth/proliferation/differentiation of tissue, hypogonadism, dysplasia of connective tissue, fibrillation of tissue, circulatory disorders, endocrine disruption, abnormality of body fluid balance, central disease, immune system disease or angiogenic disorder, comprising combining an effective amount of a polypeptide comprising the amino acid sequence represented by SEQ ID NO:7, or the amino acid sequence represented by SEQ ID NO:8, its amide or ester, or a salt thereof, with a pharmaceutically acceptable carrier, diluent or excipient.
9. A method of screening a compound that promotes or inhibits the activity of a polypeptide or its amide or ester, or a salt thereof, according to claim 2 which comprises comparing
(i) the binding when a polypeptide of claim 2 is brought into contact with tissues, cells or membrane fractions thereof, to
(ii) the binding when a polypeptide of claim 2 is brought into contact with tissues, cells or membrane fractions thereof, in the presence of a test compound, and
(iii) determining if the binding of said isolated polypeptide to the said tissues, cells or membrane fractions is increased or inhibited by the test compound.
10. A kit for screening a compound or its salt that promotes or inhibits the activity of a polypeptide or its amide or ester, or a salt thereof; according to claim 2 , comprising a polypeptide or its amide or ester, or a salt thereof; according to claim 2 .
11. A pharmaceutical composition comprising a polypeptide, its amide or ester, or a salt thereof, according to claim 2 and a pharmaceutically acceptable carrier, diluent or excipient.
12. The method of claim 8 wherein a polypeptide having the amino acid sequence represented by SEQ ID NO:7, and a polypeptide having the amino acid sequence represented by SEQ ID NO:8 are joined.
13. A method of screening a compound that promotes or inhibits the activity of a polypeptide or its amide or ester, or a salt thereof, according to claim 4 which comprises comparing
(i) the binding when a polypeptide of claim 4 is brought into contact with tissues, cells or membrane fractions thereof, to
(ii) the binding when a polypeptide of claim 4 is brought into contact with tissues, cells or membrane fractions thereof, in the presence of a test compound, and
(iii) determining if the binding of said isolated polypeptide to the said tissues, cells or membrane fractions is increased or inhibited by the test compound.
14. A kit for screening a compound or its salt that promotes or inhibits the activity of a polypeptide or its amide or ester, or a salt thereof, according to claim 4 , comprising a polypeptide or its amble or ester, or a salt thereof; according to claim 4 .
15. A pharmaceutical composition comprising a polypeptide, its amide or ester, or a salt thereof, according to claim 4 and a pharmaceutically acceptable carrier, diluent or excipient.